WILLIAM MORRIS: Open Payments
NPI 1720147150 · SANTA CRUZ, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,217 in 19 payments from 7 companies in 2025. Trend: 2023 $0 · 2024 $148 · 2025 $1,217
Long term medical supply or device loan: $997Food & beverage: $220
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 12 | $1,050 |
| Janssen Biotech, Inc. | 2 | $52 |
| PharmaEssentia USA Corporation | 1 | $31 |
| Daiichi Sankyo Inc. | 1 | $28 |
| Genmab U.S., Inc. | 1 | $22 |
| Incyte Corporation | 1 | $17 |
| AstraZeneca Pharmaceuticals LP | 1 | $16 |
Products named: KISQALI, LEQVIO, BESREMI, TECVAYLI, Enhertu, TREMFYA, Epkinly, PLUVICTO.
Industry payments across CA — which companies pay providers there.
